Pharmacy Search
Vertice Login
Menu
close

Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.
← Back to Medmonitor

Medication Type: Migraine

Zavzpret™ (zavegepant) nasal spray

Approval Date: Mar 2023

Note: New Product

Indicated for the acute treatment of migraine with or without aura

Eprontia™ (topiramate) oral solution

Approval Date: Nov 2021

Note: New Product

Indicated for the treatment of seizures, and for the preventive treatment of migraine

Zomig® (zolmitriptan) nasal spray

Approval Date: Sep 2021

Note: First-Time Generic

Indicated for the acute treatment of migraine with or without aura

Trudhesa™ (dihydroergotamine mesylate) nasal spray

Approval Date: Sep 2021

Note: New Product

Indicated for the acute treatment of migraine with or without aura

Qulipta™ (atogepant) tablets for oral use

Approval Date: Sep 2021

Note: New Product

Indicated for the preventive treatment of episodic migraine

Medication Name

Approval Date

Category

Description

Zavzpret™ (zavegepant) nasal spray

Mar 2023

Indicated for the acute treatment of migraine with or without aura

Note: New Product

Eprontia™ (topiramate) oral solution

Nov 2021

Indicated for the treatment of seizures, and for the preventive treatment of migraine

Note: New Product

Zomig® (zolmitriptan) nasal spray

Sep 2021

Indicated for the acute treatment of migraine with or without aura

Note: First-Time Generic

Trudhesa™ (dihydroergotamine mesylate) nasal spray

Sep 2021

Indicated for the acute treatment of migraine with or without aura

Note: New Product

Qulipta™ (atogepant) tablets for oral use

Sep 2021

Indicated for the preventive treatment of episodic migraine

Note: New Product
lockenvelopephone-handsetmagnifiermenucross-circle